Y-mabs Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Y-mAbs Therapeutics reported a narrowed net loss in Q2 2025, driven by reduced operating expenses, but saw a decline in DANYELZA product revenue, while announcing a definitive merger agreement at $8.60 per share.
10-Q: Y-mAbs Therapeutics Reports Q1 2025 Financial Results, Highlights DANYELZA Sales and R&D Progress
Y-mAbs Therapeutics' Q1 2025 results show increased revenue driven by international DANYELZA sales, alongside ongoing clinical trials and a business realignment strategy.
Y-mAbs Therapeutics reports a net loss of $7 million for Q3 2024, with product revenue slightly down, while advancing its DANYELZA commercialization and SADA PRIT technology platform.
Y-mAbs Therapeutics reports a net loss of $9.2 million for Q2 2024, with product revenue increasing to $22.8 million.
Y-mAbs Therapeutics reports a net loss of $6.6 million for Q1 2024, with product revenue slightly decreasing, while prioritizing DANYELZA commercialization and SADA PRIT technology development.